---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-24-006233"
form_type: "8-K"
ticker: "NDRA"
cik: "0001681682"
company_name: "ENDRA Life Sciences Inc."
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T00:58:05.153509+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# ENDRA Life Sciences reports Q1 net loss of $2.8M; advances TAEUS liver system with FDA and UK clinical study

## Summary
- Net loss of $2.8M ($0.26 per share) vs $2.9M ($0.93 per share) in Q1 2023; operating expenses $2.8M.
- Cash and cash equivalents were $1.1M as of March 31, 2024.
- First TAEUS system installed at King's College Hospital (UK) for a clinical study evaluating liver fat vs MRI (approx 75 subjects).
- FDA pre-submission meeting scheduled in Q2 2024 to align on clinical requirements for De Novo application.
- Expanded IP portfolio to 80 issued patents globally; exploring licensing for non-core indications.

## SEC filing metadata
- accession: 0001654954-24-006233
- form_type: 8-K
- ticker: NDRA
- cik: 0001681682
- company_name: ENDRA Life Sciences Inc.
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1681682/000165495424006233/0001654954-24-006233-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1681682/000165495424006233/ndra_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-24-006233
- JSON: https://secwatch.observer/filing/0001654954-24-006233.json
- Plain text: https://secwatch.observer/filing/0001654954-24-006233.txt

## Key facts
- Earnings Releases
  ENDRA Life Sciences Inc. reported the three months ended March 31, 2024 results: net income $2.8 million, or $0.26 per share, EPS $0.26 per share.
  - Period: the three months ended March 31, 2024
  - Net income: $2.8 million, or $0.26 per share
  - EPS: $0.26 per share
  - Result: reported results
  source text: Net loss in the first quarter of 2024 was $2.8 million, or $0.26 per share, compared with a net loss of $2.9 million, or $0.93 per share, in the first quarter of 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1681682/000165495424006233/0001654954-24-006233-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.